Cellectar Biosciences Inc
cellectar.comWhat Do They Do?
Develops targeted cancer drug candidates, including radioconjugates for blood cancers, solid tumors and pediatric cancers.
10-K for FY2025, filed Mar 4, 2026We are a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the…View ↗
The Company is primarily focused on the development of its radioconjugate PDC programs, also known as phospholipid radioconjugates or PRCs…View ↗
Iopofosine, a beta-emitting iodine-131 PRC, was studied in our CLOVER WaM Phase 2 study of iopofosine in patients with r/r WM where it was…View ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 13, 2026
−$6.9MView ↗
- ▲ +27% (Loss)
- vs −$5.4M in Q2 FY2025
Pipeline focus
The older report described a chemotherapy program and partnered assets alongside its iopofosine-led cancer pipeline; the latest overview centers the pipeline on radioconjugates, including candidates for solid tumors and pediatric cancers.
10-K for FY2022, filed Mar 9, 2023 10-K for FY2025, filed Mar 4, 2026Our lead PDC therapeutic, iopofosine I 131 is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer…View ↗
Our product pipeline also includes one preclinical PDC chemotherapeutic program (CLR 1900), a PDC-based alpha-emitter radiotherapeutic…View ↗
We have leveraged our PDC platform to establish three ongoing collaborations featuring four unique payloads and mechanisms of action.…View ↗
The Company is primarily focused on the development of its radioconjugate PDC programs, also known as phospholipid radioconjugates or PRCs…View ↗
CLR 125, an Auger-emitting PRC, utilizes iodine-125 as its radiation source and has been observed to show tolerability with minimal…View ↗
Iopofosine, a beta-emitting iodine-131 PRC, was studied in our CLOVER WaM Phase 2 study of iopofosine in patients with r/r WM where it was…View ↗
Loading...
